Antiplatelet Therapies

Antiplatelet therapy prevents thrombotic events in patients with acute coronary syndrome; however, the ischemic benefits come at the price of bleeding. Determining who may benefit from more potent P2Y₁₂ inhibition is not straightforward. Clinical and genetic factors influence response, and the utility of testing platelet function or genomics remains an area of debate, as does the optimal duration of dual antiplatelet therapy in patients with coronary stents.

The Antiplatelet Therapies collection offers commentary from experts in the field on the latest data and guidance for managing patients with ACS and/or DES.

Duration of Dual Antiplatelet Therapy CME
Guidelines say 12 months but duration of DAPT depends on many variables requiring clinical judgment on the part of the physician.
December 23, 2013
The Role of Intravenous and Oral Antiplatelet Agents in Acute Coronary Syndrome CME
Given the CHAMPION findings, Drs Ohman and Harrington discuss the potential integration of IV and oral P2Y₁₂ inhibition in ACS management.
December 17, 2013
CVD: Problem Solved? CME
Negative trials are almost the norm now in annual society meetings. Drs Califf and Ohman search for answers. Has CVD been essentially cured or is it a problem of trial design?
October 2, 2013

Steering Committee Members

Deepak L. Bhatt, MD, MPH
Chief of Cardiology,
VA Boston Healthcare System;
Senior Physician, Brigham and
Women's Hospital; Professor of
Medicine, Harvard Medical School;
Senior Investigator, Thrombolysis
in Myocardial Infarction (TIMI)
Study Group, Boston, Massachusetts
David J. Cohen, MD
Professor of Medicine, University of Missouri-Kansas City; Director, Cardiovascular Research, Saint Luke's Mid America Heart Institute, Kansas City, Missouri
David E. Kandzari, MD
Director, Interventional Cardiology; Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia
Gilles Montalescot, MD, PhD
Professor of Cardiology, Institut de Cardiologie, Hôpital la Pitié-Salpêtrière, Paris, France

E. Magnus Ohman, MD
Professor of Medicine; The Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease; Associate Director, Duke Heart Center; Senior Investigator, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Robert F. Storey, MD
Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield; Academic Director and Honorary Consultant in Cardiology, The Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals, Sheffield, United Kingdom
Stephen D. Wiviott, MD
Assistant Professor of Medicine, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Supported by an independent educational
grant from
Lilly

Steering Committee

Deepak L. Bhatt, MD, MPH

Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Ethicon, Inc.; Medtronic, Inc.; Sanofi; The Medicines Company

David J. Cohen, MD

David J. Cohen, MD, MSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Medtronic, Inc.; Lilly USA, LLC
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP
Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boston Scientific; Cordis Corporation; Edwards Lifesciences; Lilly USA, LLC; Medtronic, Inc.

David E. Kandzari, MD

David E. Kandzari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boston Scientific; Medtronic, Inc.; Micell Technologies, Inc.
Received grants for clinical research from: Abbott Laboratories; Boston Scientific; Medtronic, Inc.

Gilles Montalescot, MD, PhD

Gilles Montalescot, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; BIOTRONIK; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Europa; GlaxoSmithKline; Iroko Pharmaceuticals, LLC; Lead-Up; Novartis Pharmaceuticals Corporation; The Medicines Company; Medtronic, Inc.; Menarini Group; Roche
Received grants for clinical research from: Abbott Vascular; AstraZeneca Pharmaceuticals LP; BIOTRONIK; Bristol-Myer Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; Medtronic, Inc.; Nanosphere, Inc.; Pfizer Inc; Roche; Sanofi-aventis; STENTYS S.A.; The Medicines Company; Menarini Group

E. Magnus Ohman, MD

E. Magnus Ohman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; LipoScience Inc.; Merck & Co., Inc.; POZEN Inc.; Roche; Sanofi; The Medicines Company; Johnson & Johnson Pharmaceutical Reseach & Development L.L.C.
Received grants for clinical research from: Daiichi Sankyo, Inc.; Lilly USA, LLC

Robert F. Storey, MD

Robert F. Storey, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Accumetrics, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Regeneron Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Accumetrics, Inc.; AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Eli Lilly and Company; Iroko Pharmaceuticals, LLC; Merck & Co., Inc.
Received grants for clinical research from: Accumetrics, Inc.; AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Eli Lilly and Company; Merck & Co., Inc.

Stephen D. Wiviott, MD

Stephen D. Wiviott, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Merck & Co., Inc.; Eisai Inc.; AstraZeneca Pharmaceuticals LP; Aegerion Pharmaceuticals, Inc.
Served as an advisor or consultant for: Eisai Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.

	What is the best application for cangrelor in the cardiac catheterization laboratory?
		ST-segment elevation myocardial infarction (STEMI)
		High-risk, elective percutaneous coronary intervention (PCI)
		Elective, standard-risk PCI in patients without thienopyridine loading
		All of the above
		I would not use cangrelor